Bioavailability and platelet function effects of acetylsalicylic acid

Canadian Journal of Clinical Pharmacology

Volumn 3, Issue 1, 1996, Pages 29-33

  Merali, Rozina M ^a   Walker, Scott E ^a,b   Paton, Thomas W ^a,b   Sheridan, Brian L ^a   Borst, S Ian ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NOVASEN; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; ENTERIC COATED TABLET; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RADIOIMMUNOASSAY; THROMBOCYTE FUNCTION;

EID: 0029878914     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane 62 production in healthy subjects. Thrombosis Res 1980;17:317-27.
2. Bochner F, Lloyd J. Is there an optimal dose and formulation of aspirin to prevent arterial thromboembolism in man? Clin Science 1986;71:625-31.
3. Vanags D, Rodgers SE, Lloyd JV, et al. The antiplatelet effect of daily low dose enteric-coated aspirin in man: A time course of onset and recovery. Thrombosis Res 1990;59:995-1005.
4. Steinberg SK. Drug product interchangeability - clinical implication for pharmacists. Pharmacy Practice 1989;8-14.
5. Gaetano G, Cerletti C, Dejana E, et al. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 1985;72:1185-93.
6. Ali M, McDonald JWD, Thiessen JJ, et al. Plasma acetyl salicylate and platelet cyclo oxygenase activity following plain and enteric-coated aspirin. Stroke 1980;11:9-13.
7. Roberts MS, McLeod LJ, Cossum PA, et al. Inhibition of platelet function by controlled release acetylsalicylic acid formulation - single and chronic dosing studies. Bur J Clin Pharmacol 1984;27:67-74.
8. Patrono C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation 1990;81:I12-5.
9. Strom BL. Generic drug substitution revisited. N Engl J Med 1987;317:1456-74.
10. Nuotto E, Gordin A, Paasonen MK, et al. Effect of acetylsalicylic acid on plasma thromboxane 62 and platelet aggregation in man. Eur J Clin Pharmacol 1983;25:313-7.
11. Thiessen JJ, Grad H, MacLeod SM, et al. Human platelet response to three salicylate dosage forms. Biopharm Drug Dispos 1983;4:43-51.
12. Jakubowski JA, Stampfer MJ, Vaillancourt R, et al. Cumulative antiplatelet effect of low-dose enteric-coated aspirin. Br J Haematol 1985;60:635-42.
13. Rao GHR, Radha E, Johnson GJ, et al. Enteric-coated aspirin, platelet cyclooxygenase activity and function. Prostaglandins Leukot Med 1984;13:341-7.
14. Bochner F, Williams DB, Morris PMA, et al. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988;35:287-94.